EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma

Fan Ge, Tingting Wu, Xinyue Yang, Mengye Peng, Chen Yang, Kezheng Wang

Annals of Hematology · 2025-07 · 104 (7) · 3803-3819

DOI: 10.1007/s00277-025-06409-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 11.06.2025. Verfasst von Fan Ge und 5 weiteren Autor:innen. Beteiligte Einrichtung: PET-CT/MRI Department, Harbin Medical University Cancer Hospital, No.150 Haping Road, Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to evaluate the predictive value of intra-tumoral 18F-FDG metabolic heterogeneity in patients with diffuse large B cell lymphoma (DLBCL) in terms of survival. METHODS: We retrospectively included 245 patients with DLBCL who underwent 18F-FDG PET/CT prior to treatment and analyzed using total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) as metabolic volume parameters. The linear regression slopes of TMTV and TLG were calculated according to different percentages of SUV thresholds (i.e., 40%, 50%, 60%, 70%, and 80%), respectively, defined as Heterogeneity Factor-1 (HF1) and Heterogeneity Factor-2 (HF2). These indices of heterogeneity were used to predict progression-free survival (PFS). Based on the results of the Cox proportional hazards model, we constructed a multi-parameter prediction model and evaluated the model in the training and validation cohorts by calibration curve, consistency index (C-index) and decision curve analysis (DCA). RESULTS: Clinicopathological and PET/CT data from 245 patients were reviewed. 153 patients (62.4%) experienced relapse after treatment. Comparing relapsed and non-relapse patients, all 18F-FDG PET/CT parameters and heterogeneity index showed significant differences. There were significant differences in survival risk stratification according to HF1 and HF2 cut-off classifications (P < 0.0001). In multivariate Cox regression analysis, SUVmax (P < 0.0001), TLG (P < 0.0001), HF1 (P = 0.004), and HF2 (P < 0.0001) showed significant results. Among the clinicopathological parameters, IPI (P = 0.027) and Size (P < 0.0001) were selected as important parameters. CONCLUSIONS: HF1 and HF2 obtained by the linear regression slope of MTV and TLG may be a novel and useful prognostic marker in DLBCL, which can achieve survival-risk stratification of patients. In addition, multiparametric models have the potential to effectively predict the risk of recurrence in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Neoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultFeasibility StudiesAged, 80 and overRadiopharmaceuticalsPrognosisGlycolysisTumor Burden

Stichwörter der Autor:innen

Diffuse large B-cell lymphomaHeterogeneity factorMetabolic parametersProgression-free survival[18F]FDG PET/CT

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • PET-CT/MRI Department, Harbin Medical University Cancer Hospital, No.150 Haping Road, Harbin, Heilongjiang, China.
  • Department of Radiology, The First People's Hospital of Shuangliu District, West China Airport Hospital of Sichuan University, No. 120 of Chengbei Street, Dongsheng Town, Shuangliu District, Sichuan, Chengdu, 610200, Ch…
  • PET-CT/MRI Department, Harbin Medical University Cancer Hospital, No.150 Haping Road, Harbin, Heilongjiang, China. wangkezheng9954001@163.com.

Zitieren

APA

Ge, F., Wu, T., Yang, X., Peng, M., Yang, C., & Wang, K. (2025). Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma. Annals of Hematology, 104(7), 3803-3819. https://doi.org/10.1007/s00277-025-06409-8

Vancouver

Ge F, Wu T, Yang X, Peng M, Yang C, Wang K. Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma. Annals of Hematology. 2025;104(7):3803-3819. doi:10.1007/s00277-025-06409-8

BibTeX
@article{Ge2025,
  author = {Ge, Fan and Wu, Tingting and Yang, Xinyue and Peng, Mengye and Yang, Chen and Wang, Kezheng},
  title = {Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {7},
  pages = {3803--3819},
  doi = {10.1007/s00277-025-06409-8}
}
Kostenlos starten →